CYP2C9 Inhibitors

Inhibits CYP2C9, leading to increased levels of drugs metabolized by this enzyme.

Omeprazole is a proton pump inhibitor that interacts with CYP2C9, exhibiting competitive inhibition through its sulfinyl moiety. The compound's unique structure allows for specific binding to the enzyme's active site, disrupting the normal catalytic cycle. This interaction alters the enzyme's conformation, impacting substrate recognition and metabolic clearance. Furthermore, omeprazole's lipophilicity influences its bioavailability and potential for drug-drug interactions within hepatic pathways.

Fluconazole-d4 is a deuterated derivative that selectively modulates CYP2C9 activity, showcasing unique isotopic effects on metabolic pathways. Its distinct molecular structure enhances binding affinity, leading to altered enzyme kinetics. The presence of deuterium may influence hydrogen bonding and steric interactions, potentially affecting substrate specificity. Additionally, its physicochemical properties, such as solubility and stability, can impact its behavior in metabolic processes, contributing to nuanced enzyme interactions.

Sulfaphenazole is a selective inhibitor of CYP2C9, characterized by its unique sulfonamide structure that facilitates specific interactions with the enzyme's active site. This compound exhibits distinct binding dynamics, influencing the enzyme's conformation and altering its catalytic efficiency. The presence of aromatic rings enhances π-π stacking interactions, while its sulfonamide group can engage in hydrogen bonding, affecting substrate recognition and metabolic pathways. Its lipophilicity also plays a role in modulating enzyme activity.

Inhibits CYP2C9, potentially increasing the half-life of concomitant agent in researchs.

Known to inhibit CYP2C9 and alter the metabolism of CYP2C9 substrates.

Inhibits CYP2C9 among other CYP450 isoenzymes, affecting drug metabolism.

Inhibits CYP2C9, leading to increased serum levels of drugs metabolized by CYP2C9.